Miglustat (CED0006411)

Record Information
Version1.0
Creation Date2016-05-22 05:15:26 UTC
Update Date2026-08-18 03:10:27 UTC
Accession NumberCHEM018440
Identification
Common NameMiglustat
ClassSmall Molecule
Description
Miglustat belongs to the piperidines, a class of organoheterocyclic compounds within the organic compounds. This compound has the chemical formula $\text{C}_{10}\text{H}_{21}\text{NO}_4$ and an average molecular weight of 219.28 g/mol. In terms of biological activity, miglustat acts as an inhibitor of the protein target ceramide glucosyltransferase (UGCG). The compound is found in or released from three recorded sources: household cleaning and consumer products (non electric simulated smoking devices), electrical and electronic equipment (electrically stimulated smoking devices), and healthcare, pharmaceuticals and veterinary products (alimentary tract and metabolism products). The recorded route of exposure for this substance is oral.
Contaminant TypeNot Available
Chemical Structure
Synonyms
ValueSource
BuDNJChEBI
ButyldeoxynojirimycinChEBI
MiglustatumChEBI
N-(N-Butyl)deoxynojirimycinChEBI
N-Butyl deoxynojirimycinChEBI
N-Butyl-1-deoxynojirimycinChEBI
N-ButylmoranolineChEBI
NB-DNJChEBI
SC-48334ChEBI
ZavescaChEBI
BrazavesKegg
N-(N-Butyl)deoxy-nojirimycinHMDB
N-ButyldeoxynojirimycinHMDB
OGT 918HMDB
Chemical FormulaC10H21NO4
Average Molecular Mass219.278 g/mol
Monoisotopic Mass219.147 g/mol
CAS Registry Number72599-27-0
IUPAC Name(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
Traditional Namemiglustat
SMILESCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
InChI IdentifierInChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1
InChI KeyUQRORFVVSGFNRO-UTINFBMNSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as piperidines. Piperidines are compounds containing a piperidine ring, which is a saturated aliphatic six-member ring with one nitrogen atom and five carbon atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassNot Available
Direct ParentPiperidines
Alternative Parents
Substituents
  • Piperidine
  • 1,2-aminoalcohol
  • Secondary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Polyol
  • Azacycle
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Primary alcohol
  • Organopnictogen compound
  • Organic oxygen compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Biological Properties
StatusDetected and Not Quantified
OriginNot Available
Cellular LocationsNot Available
Biofluid LocationsNot Available
Tissue LocationsNot Available
ApplicationsNot Available
Biological RolesNot Available
Chemical RolesNot Available
Organoleptic EffectsNot Available
Physical Properties
StateNot Available
AppearanceNot Available
Experimental Properties
PropertyValue
Melting PointNot Available
Boiling PointNot Available
SolubilityNot Available
Predicted Properties
PropertyValueSource
Water Solubility331 g/LALOGPS
logP-1.1ALOGPS
logP-1.2ChemAxon
logS0.18ALOGPS
pKa (Strongest Acidic)12.9ChemAxon
pKa (Strongest Basic)8.49ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area84.16 ŲChemAxon
Rotatable Bond Count4ChemAxon
Refractivity55.74 m³·mol⁻¹ChemAxon
Polarizability23.99 ųChemAxon
Number of Rings1ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Spectra
Spectra
Spectrum TypeDescriptionSplash KeyDeposition DateView
Predicted GC-MSPredicted GC-MS Spectrumsplash10-0zos-3910000000-487652a19fde10ffe683Not AvailableView Spectrum
Predicted GC-MSPredicted GC-MS Spectrumsplash10-00kf-2142900000-0c0744b80c14d6b20646Not AvailableView Spectrum
Predicted GC-MSPredicted GC-MS SpectrumNot AvailableNot AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-0fk9-0190000000-1545727fb8c9dc1b2685Not AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-0ue9-6980000000-589edd008686a4fe9d4bNot AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-0a4i-9800000000-0ef03d48da73c35c0c96Not AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-014r-0690000000-52d21087091279bec38bNot AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-0fe0-3930000000-e5cf8de6350860e73852Not AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-00dl-9100000000-f8691ad25d535e38c625Not AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-014i-0090000000-32e6ad4c1e36e0f2fb66Not AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-014i-0290000000-b7fd37a3d8a9c58a1be0Not AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-0a4l-9310000000-fb18a3f257a799c2f63dNot AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-00di-0090000000-66c377bd2995bc818438Not AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-00di-2590000000-6286d923af7492795fcfNot AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-05gi-9000000000-ba860e30faee784f9ef1Not AvailableView Spectrum
1D NMR13C NMR Spectrum (1D, D2O, predicted)Not AvailableNot AvailableView Spectrum
1D NMR1H NMR Spectrum (1D, D2O, predicted)Not AvailableNot AvailableView Spectrum
Toxicity Profile
Mechanism of ToxicityNot Available
Carcinogenicity (IARC Classification)Not Available
Minimum Risk LevelNot Available
SymptomsNot Available
TreatmentNot Available
Toxicity Values
Toxicity ValueUnitValue RangeOrganismDose DescriptorRoute of ExposurePredicted or ExperimentalReference
2653.0Log mg/kg[1500:4700]RatLD50oralpredictedNot Available
Health Effects
Health EffectRelationshipDirectionReference
Exposure Sources
Source IDSourceSectorReference
272Alimentary tract and metabolism productsHealthcare, pharmaceuticals & veterinary productsNot Available
518Electrically Stimulated Smoking DevicesElectrical & Electronic EquipmentNot Available
559Non Electric Simulated Smoking DevicesHousehold cleaning & consumer productsNot Available
Pathways
2 pathways
Targets
StructureProteinUniProt IDOrganismRelationshipDetails
Click to view 3D structureNon-lysosomal glucosylceramidaseQ69ZF3Mus musculusPredicted (SEA)0.0778492
Click to view 3D structureNon-lysosomal glucosylceramidaseQ9HCG7HumansPredicted (SEA)0.155698
Click to view 3D structureSucrase-isomaltaseB5THE3Mus musculusPredicted (SEA)0.155698
Click to view 3D structureLysosomal alpha-glucosidaseP70699Mus musculusPredicted (SEA)0.155698
Lysosomal alpha-glucosidase structureClick to view 3D structureLysosomal alpha-glucosidaseP10253HumansPredicted (SEA)0.0778492
Maltase-glucoamylase structureClick to view 3D structureMaltase-glucoamylaseO43451HumansPredicted (SEA)0.0778492
Click to view 3D structureCeramide glucosyltransferaseO88693Mus musculusPredicted (SEA)0.155698
Click to view 3D structureSucrase-isomaltase, intestinalP23739Rattus norvegicusPredicted (SEA)0.0778492
Lysosomal acid glucosylceramidase structureClick to view 3D structureLysosomal acid glucosylceramidaseP04062HumansPredicted (SEA)0.233548
Sucrase-isomaltase, intestinal structureClick to view 3D structureSucrase-isomaltase, intestinalP14410HumansPredicted (SEA)0.0778492
Click to view 3D structureCeramide glucosyltransferaseQ16739HumansPredicted (SEA)0.233548
Click to view 3D structureGlycogen debranching enzymeP35573HumansPredicted (SEA)0.0778492
Click to view 3D structureAlpha-glucosidaseQ9LGC6Oryza sativa Japonica GroupPredicted (SEA)0.155698
Click to view 3D structureLysosomal alpha-glucosidaseQ6P7A9Rattus norvegicusPredicted (SEA)0.622794
Click to view 3D structureLactase/phlorizin hydrolaseP09848HumansPredicted (SEA)0.467095
Click to view 3D structureBeta-galactosidaseQ59750Sinorhizobium melilotiPredicted (SEA)0.544945
Click to view 3D structureAlpha-galactosidaseQ42656Coffea arabicaPredicted (SEA)1.71268
Beta-galactosidase structureClick to view 3D structureBeta-galactosidaseP16278HumansPredicted (SEA)2.64687
Beta-galactosidase structureClick to view 3D structureBeta-galactosidaseP00722Escherichia coli (strain K12)Predicted (SEA)0.389246
Click to view 3D structureBeta-glucosidaseP27034Agrobacterium tumefaciensPredicted (SEA)0.622794
Click to view 3D structureGlycogen debranching enzymeP35574Oryctolagus cuniculusPredicted (SEA)0.700643
IAG-nucleoside hydrolase structureClick to view 3D structureIAG-nucleoside hydrolaseQ9GPQ4Trypanosoma vivaxPredicted (SEA)0.544945
Click to view 3D structureLactase/phlorizin hydrolaseQ02401Rattus norvegicusPredicted (SEA)1.24559
Click to view 3D structureBeta-galactosidaseQ58D55Bos taurusPredicted (SEA)2.33548
Click to view 3D structurePutative beta-hexosaminidaseQ9RK76Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145)Predicted (SEA)2.95827
Concentrations
Not Available
External Links
DrugBank IDDB00419
HMDB IDHMDB0014563
FooDB IDNot Available
Phenol Explorer IDNot Available
KNApSAcK IDNot Available
BiGG IDNot Available
BioCyc IDNot Available
METLIN IDNot Available
PDB IDNot Available
Wikipedia LinkMiglustat
Chemspider ID46764
ChEBI ID50381
PubChem Compound ID51634
Kegg Compound IDNot Available
YMDB IDNot Available
ECMDB IDNot Available
References
Synthesis ReferenceNot Available
MSDSNot Available
General References
1. Moyses C: Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):955-60.
2. McCormack PL, Goa KL: Miglustat. Drugs. 2003;63(22):2427-34; discussion 2435-6.
3. Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P: Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005 Nov;80(3):223-9.
4. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE: Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007 Sep;6(9):765-72.
5. van Giersbergen PL, Dingemanse J: Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J Clin Pharmacol. 2007 Oct;47(10):1277-82. Epub 2007 Aug 24.
6. Wraith JE, Imrie J: New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag. 2009;5:877-87. Epub 2009 Nov 18.